| [1] |
程中, 陈亿, 颜宥彤, 等. 修正性减重手术的发展和反思 [J]. 中华消化外科杂志, 2022, 21(11): 1428-1431.
|
| [2] |
Sun X, Yan AF, Shi Z, et al. Health consequences of obesity and projected future obesity health burden in China [J]. Obesity (Silver Spring, Md.), 2022, 30(9): 1724-1751.
|
| [3] |
Wang Y, Zhao L, Gao L, et al. Health policy and public health implications of obesity in China [J]. The Lancet. Diabetes & Endocrinology, 2021, 9(7): 446-461.
|
| [4] |
中国营养学会肥胖防控分会, 中国营养学会临床营养分会, 中华预防医学会行为健康分会, 等. 中国居民肥胖防治专家共识 [J]. 中华流行病学杂志, 2022, 43(5): 18-26.
|
| [5] |
Jepsen MM, Christensen MB. Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity [J]. Expert Opinion on Emerging Drugs, 2021, 26(3): 231-243.
|
| [6] |
Coulman KD, Hopkins J, Brookes ST, et al. A Core outcome set for the benefits and adverse events of bariatric and metabolic surgery: The BARIACT project [J]. PLoS medicine, 2016, 13(11): e1002187.
|
| [7] |
Howick K, Griffin BT, Cryan JF, et al. From belly to brain: targeting the ghrelin receptor in appetite and food intake regulation [J]. International Journal of Molecular Sciences, 2017, 18(2): 273.
|
| [8] |
Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity [J]. Diabetes, Obesity & Metabolism, 2017, 19(9): 1242-1251.
|
| [9] |
Knudsen LB, Lau J. The discovery and Development of Liraglutide and Semaglutide [J]. Frontiers in Endocrinology, 2019, 10: 155.
|
| [10] |
Badman MK, Flier JS. The gut and energy balance: visceral allies in the obesity wars [J]. Science (New York, N.Y.), 2005, 307(5717): 1909-1914.
|
| [11] |
Gabery S, Salinas CG, Paulsen SJ, et al. Semaglutide lowers body weight in rodents via distributed neural pathways [J]. JCI insight, 2020, 5(6): e133429, 133429.
|
| [12] |
Campos CA, Bowen AJ, Schwartz MW, et al. Parabrachial CGRP neurons control meal termination [J]. Cell Metabolism, 2016, 23(5): 811-820.
|
| [13] |
Frank S, Veit R, Sauer H, et al. Dopamine depletion reduces food-related reward activity independent of BMI [J]. Neuropsychopharmacology, 2016, 41(6): 1551-1559.
|
| [14] |
Kadowaki T, Isendahl J, Khalid U, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial [J]. The Lancet. Diabetes & Endocrinology, 2022, 10(3): 193-206.
|
| [15] |
Mu Y, Bao X, Eliaschewitz FG, et al. Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial [J]. The Lancet. Diabetes & Endocrinology, 2024, 12(3): 184-195.
|
| [16] |
Chao AM, Tronieri JS, Amaro A, et al. Clinical insight on semaglutide for chronic weight management in adults: patient selection and special considerations [J]. Drug Design, Development and Therapy, 2022, 16: 4449-4461.
|
| [17] |
Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial [J]. JAMA, 2021, 325(14): 1414-1425.
|
| [18] |
Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension [J]. Diabetes, Obesity & Metabolism, 2022, 24(8): 1553-1564.
|
| [19] |
Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss [J]. Diabetes, Obesity & Metabolism, 2022, 24(1): 94-105.
|
| [20] |
Bradley CL, McMillin SM, Hwang AY, et al. High-dose once-weekly semaglutide: a new option for obesity management [J]. The Annals of Pharmacotherapy, 2022, 56(8): 941-950.
|
| [21] |
Romera I, Cebrián-Cuenca A, álvarez-Guisasola F, et al. A review of practical issues on the use of glucagon-like peptide-1 receptor agonists for the management of type 2 diabetes [J]. Diabetes Therapy: Research, Treatment and Education of Diabetes and Related Disorders, 2019, 10(1): 5-19.
|
| [22] |
赵翊如, 方振威, 张琳, 等. 基于FAERS数据库的成人使用司美格鲁肽的临床研究 [J]. 中国临床药理学杂志, 2024, 40(2): 264-268.
|
| [23] |
Nreu B, Dicembrini I, Tinti F, et al. Cholelithiasis in patients treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials [J]. Diabetes Research and Clinical Practice, 2020, 161: 108087.
|
| [24] |
Rehfeld JF, Knop FK, Asmar A, et al. Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs [J]. Scandinavian Journal of Gastroenterology, 2018, 53(12): 1429-1432.
|
| [25] |
Smits MM, Van Raalte DH. Safety of Semaglutide [J]. Frontiers in Endocrinology, 2021, 12: 645563.
|
| [26] |
Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies [J]. Gastroenterology, 2011, 141(1): 150-156.
|
| [27] |
Giorda CB, Picariello R, Nada E, et al. Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study [J]. The Lancet. Diabetes & Endocrinology, 2014, 2(2): 111-115.
|
| [28] |
Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs—FDA and EMA assessment [J]. The New England Journal of Medicine, 2014, 370(9): 794-797.
|
| [29] |
Ji L, Dong X, Li Y, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial [J]. Diabetes, Obesity & Metabolism, 2021, 23(2): 404-414.
|
| [30] |
Jeon C, Hart PA, Li L, et al. Development of a Clinical Prediction Model for Diabetes in Chronic Pancreatitis: The PREDICT3c Study [J]. Diabetes Care, 2023, 46(1): 46-55.
|
| [31] |
Bai Y, Gong G, Aierken R, et al. A retrospective study investigating the clinical significance of body mass index in acute pancreatitis [J]. PeerJ, 2024, 12: e16854.
|
| [32] |
EMA statement on ongoing review of GLP-1 receptor agonists | European Medicines Agency[EB/OL]. [2024-02-25].
URL
|
| [33] |
Ruggiero R, Mascolo A, Spezzaferri A, et al. Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database [J]. Pharmaceuticals (Basel, Switzerland), 2024, 17(2): 147.
|
| [34] |
Chen C, Zhou R, Fu F, et al. Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis [J]. European Psychiatry: The Journal of the Association of European Psychiatrists, 2023, 66(1): e99.
|
| [35] |
Zhou J, Zheng Y, Xu B, et al. Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database [J]. BMC medicine, 2024, 22(1): 65.
|
| [36] |
Wang W, Volkow ND, Berger NA, et al. Association of semaglutide with risk of suicidal ideation in a real-world cohort [J]. Nature Medicine, 2024, 30(1): 168-176.
|
| [37] |
Khaleel MA, Khan AH, Ghadzi SMS, et al. A Standardized Dataset of a Spontaneous Adverse Event Reporting System [J]. Healthcare (Basel, Switzerland), 2022, 10(3): 420.
|
| [38] |
Able C, Liao B, Saffati G, et al. Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study [J/OL]. International Journal of Impotence Research, 2024. Online ahead of print.
|